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Abstract. The availability of falsified antimalarial drugs can be reduced with effective drug regulatory agencies and
proper enforcement. Fundamental to these agencies taking action, rapid identification must be made as soon as they
appear in the market place. Since falsified antimalarials occur mostly in developing countries, performing drug analysis
presents itself with unique challenges. A fundamental factor in choosing a useful technique is affordability and simplicity.
Therefore, we suggest a three-tiered drug evaluation strategy for identifying a falsified drug in resource-poor areas. Tier I
is a simple comparison of a tablet’s weight and dimensions with official specifications. Tier II uses inexpensive photo-
metric devices (laser and fluorescence) to evaluate a tablet. Suspicious samples from Tier I and II assessments are then
subjected to a colorimetric assay for active ingredients identification and quantification. In this article, we evaluate a
novel colorimetric assay for the simultaneous assessment of both lumefantrine and artemether in co-formulated
Coartem™ tablets, and integrate the method with two novel, low-cost, fluorescence and laser photometric devices. Image
analysis software is used for the assessments. Although artemether–lumefantrine is used as an example, the strategy may
be adapted to other medicines.
INTRODUCTION
Low-income countries bear the highest proportion of deaths
caused by human immunodeficiency virus/acquired immune
deficiency syndrome (HIV/AIDS), tuberculosis, and malaria.
In 2012, an estimated 627,000 deaths were attributed to
malaria; with the disease occurring mostly in African children.1
Malaria can be cured with effective antimalarial drugs but due
to the growth of Plasmodium falciparum resistance, tradi-
tional antimalarials such as chloroquine and sulfadoxine/
pyrimethamine are no longer recommended. Although the
artemisinins are the most rapidly acting of all antimalarial
drugs,2 potential resistance has led to the abandonment of
oral artemisinin monotherapy. Therefore, this class of antima-
larial is combined with a partner drug, such as lumefantrine,
amodiaquine, piperaquine, or mefloquine, possessing a longer
half-life. This formulation, termed artemisinin combination
therapy (ACT) is recommended by the World Health Orga-
nization (WHO) as first-line treatment in most malaria-
endemic countries.3 An ACT being very widely purchased and
distributed by international and national organizations globally
combines lumefantrine (long half-life drug) with artemether
(artemisinin derivative) into a fixed-dose tablet (AMLF). The
first fixed-dose ACT, meeting the WHO prequalification
criteria for efficacy, safety, and quality is the brand Coartem™, an
AMLF drug manufactured by Novartis (Basel, Switzerland).4
As a result of the expanding market in Africa, falsified
(counterfeit) AMLF (Coartem) has already been reported in
many west and central African countries.5,6
Low-income countries with high malaria burden are easy
targets for falsified (term used to distinguish from the term
counterfeit medicines that invokes intellectual property issues)
drug manufacturers. Although these countries are relatively
poor, the prevalence of the disease contributes to a high volume
of sales, thereby making these areas lucrative locations for the
counterfeit trade. Also, weak drug regulatory and enforcement
agencies enable the counterfeiters to proliferate. The scarcity
and high cost of some medicines and unregulated markets are
also major contributors to the problem. It is imperative that a
falsified medicine be identified as quickly as possible so that
regulatory agencies and enforcement officials can take imme-
diate action, assuming that drug quality is a priority issue and
these agencies are adequately funded to take the necessary
action. Standard methods for drug quality evaluation include
high-performance liquid chromatography (HPLC) and spec-
troscopy. Because of the high cost of instruments, expensive
maintenance, lack of expertise, and less-than-ideal operational
conditions, utilization of these techniques are not practical in
low-income countries. Spectroscopic devices such as Raman
and near-infrared (NIR) can quickly and accurately scan a
sample and determine its legitimacy.7–10 These techniques do
not destroy the sample and are fairly easy to operate. The
main disadvantages of NIR and Raman spectroscopy are that
the NIR spectra are often complicated by broad and overlap-
ping absorption bands resulting from molecular overtones
and combination vibrations, while Raman spectra may be
complicated by the presence of interfering fluorescent com-
pounds. As a result, specialized software may be required to
interpret or detect subtle spectral differences. Although not
as expensive as HPLC, the spectroscopic devices are still out-
side the realm of affordability of many low-income countries
and have not been fully and independently evaluated. There
are a myriad of various field methods that are easily adaptable
in low-income countries, depending on their infrastructure
and resources. The Institute of Medicine has recently pub-
lished a report on “Countering the Problem of Falsified and
Substandard Drugs” that contains a very comprehensive
review of drug detection techniques11 and several reviews on
simple counterfeit drug field-detection techniques.12–14
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Portable field kits utilizing colorimetric techniques have
long been the choice of investigators for quickly identifying
poor quality medicines. Colorimetry has also been effectively
used to aid in identifying a falsified drug based on the absence
of the active ingredient. When counterfeit artesunate tablets
began to appear in southeast (SE) Asia,15–17 colorimetric
assays were developed to rapidly assess drug authenticity.18–21
Early methods involved a reaction of Fast Red TR salt
(FRTR) with the artemisinins (artesunate, dihydroartemisinin,
and artemether) to produce a specific yellow color.18,19 The
Global Pharma Health Fund (GPHF) incorporated the FRTR
colorimetric method for artesunate and artemether into the
GPHF-MinilabÒ; a field-adapted kit containing all required
supplies and reagents for colorimetric and thin-layer chro-
matographic analysis of essential drugs used in developing
countries.22 The FRTR technique was successfully used in
Laos and Ghana to evaluate artesunate quality,13,23 but as
the new ACTs were becoming recommended treatment, oral
artemisinin monotherapy was phased out. Many of the new
ACTs combined the artemisinins with yellow-colored partner
drug such as lumefantrine and amodiaquine in a fixed-dose
co-formulation, thereby making the FRTR test obsolete. As
an alternative, Ioset and Kaur produced a colorimetric test
that resulted in a blue or pink product when positive for the
artemisinins.21 One of the most widely used ACTs is the
artemether–lumefantrine co-formulated tablet. Nyarko and
Nettey have combined a colorimetric test with image analysis
software to quantitatively assess lumefantrine and artemether
in tablets collected in Ghana.24 Although colorimetry as well
as thin-layer chromatography (TLC) are relatively inexpensive,
spectroscopic (Raman, NIR) methods have useful advantages
in resource-challenged countries. These advantages include a
high throughput, high accuracy, and no sample preparation
that eliminates the use of solvents, chemicals, or labware.
These methods are usually qualitative, mostly for rapid screen-
ing of suspicious medicines. Incorporating multivariate analy-
sis techniques with NIR and Raman spectral comparisons,
falsified artesunate tablets have been successfully identified
with 100% accuracy.8,10 Substituting complex multivariate
analysis with a simple spectral correlation value (1.00 = a
perfect spectral match), our laboratory conducted a compari-
son of NIR and Raman analysis on 24 confirmed falsified
Guilin Pharmaceutical Co. (Shanghai, China) brand artesunate
tablets. Raman analysis demonstrated both sensitivity and
specificity of 100%, while NIR analysis resulted in sensitivity
and specificity of 80% and 100%, respectively. In regard to
AMLF tablets, the Raman spectra showed a large distinct
band correlating to the relative concentration of the
lumefantrine active ingredient present in the tablet. This char-
acteristic has the potential to be useful for quantitative analy-
sis of lumefantrine in AMLF tablets of various brands.
Because of its portability and lower cost, we suggest Raman
spectroscopy to be better suited for field analysis. Table 1 lists
the types of tests suggested for use in the field and are
grouped by tiers; with Tier I being the least complex in terms
of equipment, training, and affordability and Tiers II and III
increasing in complexity. Tier I consists of simple physical
measurements (e.g., tablet weight and dimensions) where
many falsified medicines outside the specification limits can
be identified. Tier II suggests the use of rapid scanning tech-
niques using photometric devices followed by techniques
requiring more advanced technical expertise such as colori-
metric assays and TLC (Tier III). The suggested strategy is to
initially assess tablets using Tier I and II techniques, which
are not destructive to the sample and does not require the use
of chemical reagents or solvents. Tier III techniques are
reserved for suspicious tablets failing Tiers I and II assess-
ments, thereby conserving the transport and use of toxic and/
or flammable chemicals used for Tier III. Quantitative Tier III
assessments are important in identifying counterfeits containing
active ingredients, since substandard amounts can contribute to
drug resistance. In lieu of expensive Raman or NIR devices
listed in the Tier II group in Table 1, we propose the use of two
novel, low-cost, handheld, and nondestructive counterfeit drug
screening devices: the counterfeit detection device version 3
(CD-3)25 developed at the U.S. Food and Drug Administration
Table 1
Comparison of tests in terms of tier category






Dimensions Quantitative Inspector* Field Micrometer or
caliper (0.1 mm)
< 100 No No
Weight Quantitative Inspector* Field Portable balance
(0.001 g), batteries
< 100 No No
Visual color Qualitative Inspector* Field None 0 No No
Photometric (Tier II)
Raman (portable) Qualitative Inspector† Field Device, batteries > 10,000 No No
NIR (portable) Qualitative Inspector† Field Device, batteries > 10,000 No No
CD-3 Qualitative Inspector† Field Device, batteries ~1,000 No No




Basic laboratory TLC plates, labware,
developing chamber,
sprayer, chemicals







Basic laboratory Labware, chemicals < 100 Yes Yes
Quantitative
Semi-quantitative
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(FDA) and a laser-emitting photometric device counterfeit
drug indicator (CoDI) developed by Michael D. Green.
The CD-3 is a compact handheld device with a series of
light-emitting diodes (LEDs) of various wavelengths. A sam-
ple is illuminated by a selected wavelength and the image is
visualized with a charged-couple device (CCD). Depending
on the formulation, the tablet may reflect a particular wave-
length differently (fluorescence) resulting in characteristic
intensities for a particular product. By comparing with an
authentic sample, suspicious products are visually distinguish-
able. Samples may be visualized without compromising the
blister pack containing the tablets. The CD-3 is relatively
inexpensive (< 1,000 USD), robust, accurate, and easy to
operate. The CD-3 was recently evaluated on counterfeit and
genuine artesunate tablets collected in Laos, demonstrating
100% positive predictive value and 97.4% negative predictive
value.25 The features of the CD-3 can also be used to distin-
guish counterfeit packaging because of the use of different
quality inks as well as the appearance of covert markings.
Since falsified medicines may include repackaged expired
product, this feature of the CD-3 is extremely useful.
The CoDI is a battery-operated handheld device incorpo-
rating a 405-nm laser, a photoresistor, and digital voltmeter as
the main components. A tablet is placed in the sample well,
and the amount of laser light passing through the tablet is
measured using the photoresistor and voltmeter. The intensity
of light detected by the photoresistor results from a combina-
tion of the following parameters: 1) tablet thickness, 2) tablet
density, and 3) wavelength of light emitted by the tablet
matrix (fluorescence) relative to the spectral response of the
cadmium sulfide (CdS) photoresistor. Use of colored filters in
conjunction with the fluorescent properties of the tablet pro-
vides a unique value for the light intensity emitted through
the tablet. The device is nondestructive to the tablet, low cost
(< 100 USD), simple to use, and provides rapid results.
The primary objective of this article was to evaluate a
three-tiered falsified drug identification strategy designed
for use in resource-poor countries. A collection of falsified
Coartem tablets was used for the evaluation. The sources of
the tablets were not identified because of security issues. The
strategy consists of an initial physical evaluation by simple
measurements of tablet weights and dimensions (Tier I),
followed by rapid scanning of the tablets using the CD-3 and
CoDI devices (Tier II). Suspicious tablets, as determined
from Tier I and II, are then subjected to a colorimetric test
to identify and quantify the active ingredients (Tier III).
Previously described colorimetric tests for the artemisinins
required reagents not readily available in many developing
countries.18–21 We have developed a simple colorimetric test
for lumefantrine and artemether in a single-tablet solution
using only sulfuric and acetic acid. These commonly used
acids are inexpensive and stabile. Unfortunately, sulfuric acid
has been frequently used in the illicit manufacture of narcotics,
therefore large amounts distributed through international
commerce have become controlled. Although, its availability
and acquisition may limit its application in the field, the small
amounts necessary for the colorimetric assay may be less
problematic. Both lumefantrine and artemether are completely
dissolved in acetic acid. The intensity of the inherent yellow
color of lumefantrine as well as the orange/red product of an
artemether/sulfuric acid reaction product is assessed using
image analysis software.
The primary aim of this article was to evaluate tablet mea-
surements (Tier I), CD-3 and CoDI (Tier II), and the colori-
metric acid test (Tier III) as a rapid, simple, and low-cost
strategy for identifying counterfeit Coartem tablets in resource-
poor, low-income countries.
MATERIALS AND METHODS
Physical: Weights and dimensions. Sample tablets were
weighed using an analytical balance (0.001 g precision), and
tablet thickness and diameter were measured using digital
calipers (0.01 mm precision). The official specification ranges
for the weight and thickness of an authentic Coartem tablet
are 0.228–0.252 g and 3.0–3.4 mm, respectively (Novartis,
personal communication). A diameter range of 9.1–9.2 mm
was determined from the measurements of 12 authentic
Coartem tablets.
Colorimetric assay: Preparation of calibration standards.
Secondary calibration standards were prepared by combining
several authentic Coartem tablets and analyzing for lume-
fantrine (LF) and artemether (AM) content by HPLC. In brief,
tablets were pulverized and a weighed portion added to a solu-
tion of 10% acetic acid in methanol. After sonication for
20 minutes, the sample was filtered through a 0.45-mm nylon
membrane and injected into the HPLC. The components were
separated using 150 + 4.6 mm C18, 5-mm column (Supelco Inc.
Bellefonte, PA) with a mobile phase consisting of 60% aceto-
nitrile and 40% 0.05 M sodium perchlorate (pH 2.5) at a flow
rate of 1 mL/min. Detection was accomplished with ultraviolet
(UV) absorbance at 210 nm. Quantitation of the sample was
made by direct comparison with pure authentic LF and AM
standards. Once the amount of LF and AM was established
for the tablet mixture, glacial acetic acid was added to achieve
a LF concentration of 36 mg/mL and an AM concentration of
6 mg/mL. These concentrations represent 120% of the active
pharmaceutical ingredients (APIs) of a typical tablet (AM/LF
20 mg/120 mg) dissolved in 4 mL glacial acetic acid. Subsequent
dilutions were made to obtain 100% (30 mg/mL LF, 5 mg/mL
AM), 80% (24 mg/mL LF, 4 mg/mL AM), 50% (15 mg/mL LF,
2.5 mg/mL AM), 25% (7.5 mg/mL LF, 1.25 mg/mL AM), and
10% (3.0 mg/mL LF, 0.5 mg/mL AM).
Colorimetric assay for lumefantrine and artemether cali-
bration samples. Of the filtered solution (0.45 mm nylon
filter), 100 mL was transferred to the wells of a clear poly-
styrene 96-well flat-bottomed plate in triplicate. The wells
were analyzed with a plate reader (SpectraMax 250; Molec-
ular Devices, Sunnyvale, CA) set for absorbance at 420 nm
for LF analysis and a digital photograph taken (PowerShot
A3100 IS Camera; Canon, Lake Success, NY) after placing the
plate on a light box (Visual Plus SV 450; Fujifilm, Greenwood,
SC). Image analysis was performed using MVHimagePCv8
software (MVHimagePCv8, Global Systems Science, Uni-
versity of California). Red, green, and blue pixels for each
well were measured and normalized to blue (RvsB = [Red –
Blue]/[Red + Blue]) for LF and green for AM (RvsG =
[Red – Green]/[Red + Green]). These image analysis values
were chosen based on acceptable linearity relative to con-
centration. One drop (~20 mL) of concentrated sulfuric acid
was added to each well and allowed to react at room tem-
perature for 30 minutes. The orange/red color, developed in
the presence of AM, was measured by absorbance at 520 nm
followed by image analysis as described above. The linearity
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of concentration versus absorbance and RvsB values were
plotted and evaluated using Sigmaplot version 12.3 (SYSTAT
Software Co., San Jose, CA). Correlations between RvsG and
absorbance for LF and AM were also plotted. Specificity of
the colorimetric assay was assessed by applying the procedure
described above to solutions of typical doses of excipients and
commonly used antimicrobials.
Colorimetric assay procedure for tablets. A single tablet of
fixed dose LF/AM (120/20 mg) was weighed and the dimen-
sions (diameter and thickness) were measured with a digital
caliper. The tablet was placed into a glassine paper envelope
and pounded to a fine powder using a pestle. The powdered
sample was transferred to a glass vial and 4 mL glacial acetic
acid was added. The sample was shaken vigorously for 15 sec-
onds. After 30 minutes at room temperature, the sample was
shaken again. When the undissolved particulates settled to
the bottom, 100 mL filtered solution was transferred to the
wells of a 96-well plate and subjected to image analysis and
chemical treatment as described above for the calibration
samples. The assay was applied to an authentic Coartem tab-
lets and suspected falsified tablets.
CD-3 analysis.A CD-3 device was a graciously loaned to us
by the FDA. The authentic Coartem tablets and suspected
counterfeit tablets used for the colorimetric assay were
scanned using the CD-3 prior to performing the colorimetric
assay. The detection mode was set for infrared (IR) filter and
scanned using the UV wavelength LED. Tablet brightness
resulting from the fluorescence produced by the UV LED on
the tablet surfaces were measured as “gray values” using
ImageJ software (ImageJ version 1.45s; National Institutes of
Health, http://imageJ.nih.gov/ij). A plot of gray values across
the diameter of each tablet was determined from a digital
photograph taken with the CD-3.
CoDI laser analysis. A prototype CoDI, as described in
the introduction, was evaluated using 12 authentic and
7 counterfeited Coartem tablets as well as two other brands
of AM/LF tablets from various batches. Twelve groups of five
tablets of common antimalarials were also assessed using the
CoDI. The samples included artesunate, chloroquine, meflo-
quine, and sulfadoxine/pyrimethamine of various brands or
manufacturers. The authenticities of the Coartem tablets were
confirmed from Raman scans and HPLC analysis. Specific
operational details of the CoDI were not disclosed because
of potential patent issues. Each sample tablet was placed in a
compartment from which a 405-nm laser beam is emitted. The
intensity of light emitted through the tablet was recorded
using a photoresistor coupled to a voltmeter. A red filter was
then placed over the photoresistor and the intensity rerecorded
from the same tablet. A CoDI value (W) was calculated from
the difference and ratio of light intensity (I) with and without
the filter [W = (I – Ifilter)/(Ifilter/I)]. Box-and-whisker plots
26
were used to compare values for each group of samples to
evaluate the CoDI in terms of its specificity for Coartem.
Nonparametric Mann–Whitney test (MedCalc version 13.2.0.0;
MedCalc Software bvba, Osten, Belgium) was used to evaluate
significant differences between the Coartem group and the
other drugs analyzed.
RESULTS
Physical: Weights and dimensions. Table 2 shows the
weights and dimensions of the sample tablets relative to the
range expected for authentic tablets. Any tablet’s measure-
ments falling outside the acceptable range would be consid-
ered as “failed.” Except for CF #2 and CF #6, all the samples
failed. This information along with the photometric results
was used to determine if the sample should undergo the
colorimetric test.
Colorimetric assay. Figure 1A shows the linear relationship
of the LF concentrations relative to absorbance (R2= 0.999)
and R versus B (R2 = 0.991) of the acetic acid extract from
an authentic pharmaceutical preparation. Good correlation
Table 2








CF #1 306 9.2 3.4 Fail
CF #2 241 9.2 3.2 Pass
CF #3 343 9.2 3.7 Fail
CF #4 304 10 3.7 Fail
CF #5 260 9.3 3.5 Fail
CF #6 243 9.2 3.2 Pass
CF = counterfeit.
Bold/italic figures were used to emphasize values that were out-of-range for the Coartem
specifications.
*Coartem tablet specifications per Novartis personal communication.
†Range as determined from 12 authentic tablets.
‡Pass = tablet measurements within all three ranges; fail = tablet measurement outside of
at least one range.
Figure 1. Comparison of the linearities and correlations of the
colorimetric test for lumefantrine (A) and artemether (B) when
analyzed by absorbance and image analysis techniques.
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(R = 0.995) between absorbance and R versus B pixel image
analysis for LF was observed. Linearity of AM relative to
concentration, and the correlation between absorbance and
image analysis (R versus G) are shown in Figure 1B.
Although the correlation between absorbance and R versus
G was good (R = 0.997) for AM, there was more variability in
the colored product (R = 0.955 for R versus G, R = 0.982 for
absorbance) from the reaction of artemether with sulfuric/
acetic acid. The specificity of the colorimetric method in
terms of the observed color produced for common excipients
and other commonly used drugs are listed in Table 3. Of the
compounds tested, primaquine and tetracycline were soluble
enough in acetic acid to produce a yellow/orange color while
the slight solubility of amodiaquine resulted in a weak yellow
color. On treatment with sulfuric acid, the color of the com-
pounds remained; although less intense for primaquine.
Artemisinin and its derivatives all produced a yellow/orange/
red-colored product, while erythromycin turned black. The
colorimetric assay was applied to a set of known counterfeits
and compared with an authentic reference tablet (Figure 2A).
The acetic acid extracts and subsequent color reaction with
sulfuric acid for this set of tablets are shown in Figure 2C and
D, respectively. Although all the tablets appeared yellow,
the yellow product was not soluble in acetic acid for samples
CF #1, CF #2, CF #4, and CF #5. Sample CF #3 showed a
yellow product, but was not LF as confirmed by HPLC and
Raman spectroscopy, while the yellow product in sample
CF #6 was confirmed to be LF at the proper concentration
for an authentic product. Image analysis was performed on
colors (R versus B for LF) and (R versus G for AM) from the
samples in Figure 2C and D. Since the image analysis results
were shown to be linear relative to concentration, the %API
was calculated as a percent of the authentic reference tablet
(Figure 3). Since no colors were apparent for either LF or AM
for CF #1, CF #2, CF #4, and CF #5, these samples were
considered to be falsified products based on the absence of
both active ingredients via the colorimetric assay. Sample
CF #3 showed a yellow product equivalent to 121% LF and
no artemisinin derivative. The colorimetric test indicated the
absence of one of the active ingredients, and therefore this
sample would be designated a counterfeited product. Analysis
of CF #3 by HPLC and Raman spectrometry showed no
detectable levels of LF. In this case, the yellow product in
CF #3 is extractable in acetic acid and mimics the presence of
LF. The colorimetric test showed CF #6 to contain both
LF (111%) and AM (135%). HPLC analysis revealed this
Table 3
Specificity of the colorimetric test to common excipients and other
antimicrobials
Compound Acetic acid extract Sulfuric acid treatment
Excipients




























Amodiaquine Weak yellow Weak yellow
Lumefantrine Yellow Yellow
Figure 2. (A) Photograph of falsified (counterfeit [CF] #) and authentic tablets, (B) CD-3 visual fluorescence, (C) tablet material dissolved in
acetic acid, and (D) subsequent colorimetric reaction of artemether with sulfuric acid.
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sample to contain appropriate amounts of both of the active
ingredients, 108% LF and 112% AM. It is suggested that
samples showing a positive colorimetric test should subse-
quently be analyzed by standard HPLC methods to determine
accurate %APIs.
CD-3 analysis. Figure 2B is a digital photograph of the sam-
ple tablets taken with the CD-3 and shows the comparative
intensities of the tablet fluorescence. Samples CF #1, CF #2,
CF #4, CF #5, and CF #6 were noticeably brighter than the
authentic tablets, while CF #3 was visibly darker. It should be
noted that sample CF #6, which contained the correct
amounts of active ingredients, was substantially brighter; indi-
cating a suspected counterfeit. A CD-3 scan of the packaging
revealed inconsistencies of various inks relative to the authen-
tic reference package (image not shown for security purposes).
A diode array UV spectrum of the chromatographic peak for
artemether revealed contamination or possible degradation.
It has been observed in our laboratory that artesunate tablets
subjected to elevated temperatures tended to fluoresce more
than samples kept under normal conditions. Therefore, it is
suspected that sample CF #6 may have been an expired/
degraded product, which may have been repackaged to
resemble a legitimate product with an altered expiration date.
CoDI analysis. Figure 4 shows box-and-whisker plots for
each group of drugs analyzed by the CoDI. The median value
of “W” for the authentic Coartems is 1.88 (range: 1.30–3.25,
N = 12). All counterfeit Coartems (CF #) were outside the
range; including CF #6 (W = 0.30). All the groups of drugs
were significantly different (P < 0.002, Mann–Whitney test)
from the authentic Coartem group indicating this technique to
be very specific to Coartem.
DISCUSSION AND CONCLUSIONS
The main concerns for accurate field testing of antimalar-
ials in resource-poor countries are the affordability and the
regional availability of associated reagents and equipment
and human capacity. The colorimetric test described in this
article assesses the inherent yellow coloration of lumefantrine
dissolved in acetic acid without the use of reactants, followed
by the addition of sulfuric acid that reacts with artemether
forming a red/orange reaction product. A search for African
suppliers of chemicals through Alibaba.com, a leading plat-
form for global wholesale trade, revealed 12 suppliers for
concentrated sulfuric acid and 23 suppliers for glacial acetic
acid. Therefore, these chemicals are assumed to be much
more easily procured in Africa relative to the reactants Fast
Red TR salt, dinitrophenylhydrazine, and Fast Blue RR used
in other colorimetric methods for the artemisinins. A search
for these reactants through Alibaba.com revealed no African
suppliers. The acids used in the colorimetric test are caustic,
therefore care should be used when performing the assay and
personal protective equipment such as gloves and safety
glasses are essential. The colorimetric reaction is based on
the Zak reaction, which was initially applied to cholesterol
analysis using acetic acid and sulfuric acid in the presence of
Fe3+ as an oxidizing agent.27 Artemisinin and its derivatives
are sesquiterpene lactone compounds possessing a reactive
endoperoxide group. Therefore, this compound can act as its
own oxidizing agent in the absence of Fe3+, making this reac-
tion highly specific for the artemisinins (Table 3). It is
suspected the colored reaction product is a conjugated poly-
ene derived from oxidation and dehydration of the sesquiter-
pene lactone. Optimum intensity of the red/orange product
occurs in 30–60 minutes and progressively turns to a dark
brown at ambient temperatures. The color intensity is linearly
proportional to the concentration, allowing direct propor-
tional comparisons with an authentic reference standard tab-
let. The color intensity can be measured by image analysis of
red, green, and blue pixels from a digital photograph or
directly using smartphone image analysis applications. Image
analysis techniques have been successfully used in colori-
metric assays for the determination of deltamethrin levels
on insecticide-impregnated mosquito nets.28,29 To minimize
transportation and usage of the reagents as well as increase
throughput, it is suggested the tablets be initially scanned
using nondestructive techniques that do not require sample
preparation (Tier II).
The CD-3 has been fully evaluated in the field on artesunate
samples collected in SE Asia.25 A total of 203 tablets were
analyzed and compared with authentic tablets, resulting in a
specificity, sensitivity, and positive predictive values of 100%,
Figure 3. Colorimetric test intensities using image analysis tech-
niques. Values determined by direct comparison with the authentic
reference tablet.
Figure 4. Counterfeit drug indicator (CoDI) box-and-whisker plot
of “W” values [W = (I – Ifilter)/(Ifilter/I)] from 12 authentic Coartems
and 6 counterfeited ones and their comparison withW values for other
commonly used antimalarials. The W values for the counterfeits were
well outside the range found for the authentics while all the W values
of the other drugs (N = 5 for each brand/manufacturing) were signifi-
cantly different (P < 0.002, Mann–Whitney test).
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98.4%, and 100%, respectively. All observations were made
by visual interpretation with interobserver (N = 3) agreement
of 100%. In this study, the CD-3 was used to evaluate a
collection of confirmed falsified Coartem tablets relative to an
authentic reference sample. Confirmation of falsified samples
was established by Raman scans, HPLC, or inconsistencies of
the packaging print relative to an authentic package. Although,
the CD-3 has multiple LEDs that emit light of various wave-
lengths with both a visible and IR modes of detection, we
used the UV LED as the light source in IR detection mode
for the Coartem analysis (Figure 2B). The counterfeits were
bracketed in the top left and bottom right corners by authentic
tablets, which were stored under nominal conditions (i.e., in
the blister pack at room temperature) and used within the
expiry date. Visual interpretation clearly reveals differences
in brightness relative to the authentic tablets. To allow for a
more objective interpretation, we also incorporated image
analysis techniques to compare the fluorescence intensity of
the samples from a digital photograph (Figure 5). Image anal-
ysis software has been incorporated into a newer version of
the CD-3, termed the CD-4. Note that tablet sample CF #6 is
slightly more fluorescent relative to the authentics, although it
has the correct amounts of active ingredients, as determined
by HPLC analysis. Diode array analysis of the spectral purity
associated with the artemether chromatographic peak showed
a high level of impurities, suggesting a degraded product.
Since the CD-3 scan of the packaging suggests a counterfeited
product, it is assumed that expired/degraded Coartem tablets
were repackaged with another expiration date. We observed
that the fluorescence of artesunate tablets stored at higher
temperatures (40°C) increased relative to those stored at
ambient temperatures (25°C). Therefore, tablet fluorescence
intensities may be affected by degradation products. Thus, the
CD-3 may be useful in determining if medications have been
stored properly. Authentic tablets typically produce consis-
tent fluorescence intensities and any deviation would be con-
sidered as a suspected counterfeit. However, a counterfeited
product can contain a variety of ingredients; therefore, a sam-
ple with similar intensity to the reference tablet does not
necessarily indicate an authentic sample.
The CoDI is a novel device that measures the amount of
laser light being transmitted through a tablet. Depending on
the composition of the tablet, the use of a near-UV laser may
result in a color change of the transmitted light. The change in
the emitted wavelength (fluorescence) is characteristic of par-
ticular brands of tablets and can be used to distinguish these
drugs from counterfeits or other brands. Figure 6 shows the
various colors and intensities emitted from commonly used
antimalarial drugs using the 405-nm laser placed behind the
tablet. Under normal light, all these tablets appear white.
Digital photographs of the emitted colors can be analyzed
Figure 5. CD-3 fluorescent intensities as measured from the pho-
tograph (Figure 2B) using image analysis techniques. The level of
intensity for authentic tablets including the reference is indicated by
the dotted line.
Figure 6. Colors produced by various antimalarials using the counterfeit drug indicator (CoDI), demonstrating its fluorescent properties when
a near-ultraviolet (near-UV) laser is placed behind the sample tablet.
Table 4










CF #1 Fail Fail Fail Fail
CF #2 Pass Fail Fail Fail
CF #3 Fail Fail Fail Fail
CF #4 Fail Fail Fail Fail
CF #5 Fail Fail Fail Fail
CF #6 Pass Fail Fail Pass
CD-3 = counterfeit detection device version 3; CoDI = counterfeit drug indicator;
CF = counterfeit.
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by image analysis software to distinguish between brands or
identify counterfeits. Smartphone image analysis apps can
provide rapid real-time color comparisons of samples.
An objective of this article is to illustrate the use of multiple,
simple, and low-cost techniques to accurately identify a coun-
terfeit drug. Here, we use the popular and effective antimalar-
ial drug Coartem as an example. We recommend a three-tiered
system: 1) physical properties of a tablet (e.g., weights and
dimensions), 2) photometric techniques for rapid scanning
(e.g., CD-3 and CoDI), and 3) colorimetric techniques for
identification and quantification of active ingredients. Chemicals
used for the colorimetric tests (Tier III) are conserved, since it
was used only for the samples failing the photometric scans
(Tier II). Table 4 gives a summary of the test results for six
counterfeited Coartem tablets. Tier I tablet measurements
show CF #2 and CF #6 to be within acceptable limits, while
Tier III colorimetric results show CF #6 to pass quantitative
limits for the active ingredients. Tier II qualitative photometric
analysis was able to distinguish all the samples as suspicious,
that is, counterfeited or degraded. It is recommended that
liquid chromatography–mass spectrometry (LC-MS) techniques
be used for confirmation.30
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